Maxigen Biotech (TPE:1783) Forward Dividend Yield %: 2.18% (As of Jun. 29, 2026)


TPE:1783 Maxigen Biotech Inc TPE:1783
87 GF Score
Price NT$38.80
GF Value NT$60.99
Valuation Significantly Undervalued
View Full Analysis

What is Maxigen Biotech Forward Dividend Yield %?

Maxigen Biotech TPE:1783 +1.84% 87 Forward Dividend Yield % is 2.18% as of Jun. 29, 2026. GuruFocus rates TPE:1783 with a GF Score™ of 87/100 and a GF Value™ of NT$60.99 (Significantly Undervalued). Among 315 Medical Devices & Instruments companies, Maxigen Biotech ranks better than 50.79% on this metric.

As of today (2026-06-29), the Forward Annual Dividend Yield of Maxigen Biotech is 2.18%.

As of today (2026-06-29), the Trailing Annual Dividend Yield of Maxigen Biotech is 2.18%.

TPE:1783's Forward Dividend Yield % is ranked better than
50.79% of 315 companies
in the Medical Devices & Instruments industry
Industry Median: 2.06 vs TPE:1783: 2.18

Maxigen Biotech's Dividends per Share for the three months ended in Dec. 2025 was NT$0.00.

During the past 12 months, Maxigen Biotech's average Dividends Per Share Growth Rate was -16.90% per year.

During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Maxigen Biotech was 69.50% per year. The lowest was -9.50% per year. And the median was 16.40% per year.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Maxigen Biotech  (TPE:1783) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Maxigen Biotech Forward Dividend Yield % Related Terms


TPE:1783 vs ISRG, BDX, MDLN: Forward Dividend Yield % Comparison

For the Medical Instruments & Supplies subindustry, Maxigen Biotech's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maxigen Biotech Forward Dividend Yield % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Maxigen Biotech's Forward Dividend Yield % falls into.


TPE:1783
87GF Score
Maxigen Biotech Inc TPE:1783
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maxigen Biotech Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Maxigen Biotech Recent Full-Year* Dividend History

Amount Ex-date Record Date Pay Date Type Frequency Forex Rate
TWD 0.8299632025-09-052025-09-082025-09-30Cash DividendannuallyTWD:TWD 1.000000

* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.

Maxigen Biotech's Forward Annual Dividend Yield (%) for Today is calculated as

Forward Annual Dividend Yield=Forward Full Year Dividend/Current Share Price
=0.829963/38.80
=2.14 %

Current Share Price is NT$38.80.
Maxigen Biotech's Dividends per Share for the forward twelve months is calculated as NT$0.829963 * 1 = NT$0.829963.

Maxigen Biotech's Trailing Annual Dividend Yield (%) for Today is calculated as

Trailing Annual Dividend Yield=Most Recent Full Year Dividend/Current Share Price
=0.829963/38.80
=2.14 %

Current Share Price is NT$38.80.
Maxigen Biotech's Dividends per Share for the trailing twelve months (TTM) ended in Today is NT$0.829963.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Forward Dividend Yield % of 2.18% mean?
Maxigen Biotech (TPE:1783) has a Forward Dividend Yield % of 2.18% as of Jun. 29, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Maxigen Biotech and its competitors. According to the industry distribution chart, Maxigen Biotech ranks #155 out of 315 companies in the Medical Devices & Instruments industry, placing it in the top 49.2%.
Is Maxigen Biotech's Forward Dividend Yield % too high?
Maxigen Biotech's current Forward Dividend Yield % is 2.18%. The Medical Devices & Instruments industry median Forward Dividend Yield % is 2.06. Maxigen Biotech's value of 2.18% is 5.8% above this industry median. Based on the distribution chart, Maxigen Biotech ranks #155 out of 315 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Maxigen Biotech has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's Forward Dividend Yield % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Maxigen Biotech ranks #155 out of 315 companies for Forward Dividend Yield %. This puts Maxigen Biotech in the upper half of its industry. The industry median Forward Dividend Yield % is 2.06. Maxigen Biotech's value of 2.18% is 5.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Devices & Instruments company?
The median Forward Dividend Yield % among Medical Devices & Instruments companies is 2.06, based on 315 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maxigen Biotech's current Forward Dividend Yield % of 2.18% is 5.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Maxigen Biotech and its competitors. For the Medical Devices & Instruments industry, the median Forward Dividend Yield % is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maxigen Biotech's current Forward Dividend Yield % is 2.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$60.99, compared to a current price of NT$38.80 — trading 36.4% below its estimated fair value. The current Forward Dividend Yield % is 2.18% and 5.8% above the Medical Devices & Instruments industry median of 2.06. Maxigen Biotech's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current Forward Dividend Yield % is 2.18% as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Maxigen Biotech (TPE:1783) Overvalued in 2026?

Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued. The current stock price of NT$38.80 is trading 36.4% below its estimated GF Value™ of NT$60.99. GuruFocus considers Maxigen Biotech to be Significantly Undervalued.

Key valuation signals for TPE:1783:

  • Forward Dividend Yield %: 2.18%
  • GF Value™: NT$60.99 vs. price of NT$38.80 (36.4% below fair value)
  • GF Score™: 87/100
  • Industry Position: 5.8% above the Medical Devices & Instruments median (#155 of 315)

No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Maxigen Biotech Business Description

Address No.88, Keji 1st Road, Guishan District, Taoyuan City, TWN, 333
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score

Get the complete analysis for TPE:1783

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$38.80
Price
NT$60.99
GF Value